Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Wang P, Song X, Cao D, et al. Oncogene-dependent function of BRG1 in hepatocarcinogenesis. Cell Death Dis. 2020;11(2):91. doi:10.1038/s41419-020-2289-332019910
   PubMed Web of Science ®Google Scholar
• Zhang G, Tang X, Liang L, et al. DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma. Oncogene. 2020;39(16):3229–3244. doi:10.1038/s41388-020-1215-632071398
   PubMed Web of Science ®Google Scholar
• Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of hepatocellular carcinoma in the Precision Medicine era: from treatment stage migration to therapeutic hierarchy. Hepatology. 2020. doi:10.1002/hep.31187
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519–530. doi:10.1085/jgp.8.6.51919872213
   PubMedGoogle Scholar
• Sanderson SM, Locasale JW. Revisiting the Warburg effect: some tumors hold their breath. Cell Metab. 2018;28(5):669–670. doi:10.1016/j.cmet.2018.10.01130403984
   PubMed Web of Science ®Google Scholar
• Wang T, Marquardt C, Foker J. Aerobic glycolysis during lymphocyte proliferation. Nature. 1976;261:4.
   Web of Science ®Google Scholar
• Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47. doi:10.1016/j.cmet.2015.12.00626771115
   PubMed Web of Science ®Google Scholar
• Novikova MV, Khromova NV, Kopnin PB. Components of the hepatocellular carcinoma microenvironment and their role in tumor progression. Biochemistry (Mosc). 2017;82(8):861–873. doi:10.1134/S000629791708001628941454
   PubMed Web of Science ®Google Scholar
• Sharabi K, Tavares CD, Rines AK, Puigserver P. Molecular pathophysiology of hepatic glucose production. Mol Aspects Med. 2015;46:21–33. doi:10.1016/j.mam.2015.09.00326549348
   PubMed Web of Science ®Google Scholar
• Goldstein I, Hager GL. Transcriptional and chromatin regulation during fasting - the genomic era. Trends Endocrinol Metab. 2015;26(12):699–710. doi:10.1016/j.tem.2015.09.00526520657
   PubMed Web of Science ®Google Scholar
• Hirata H, Sugimachi K, Komatsu H, et al. Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. Cancer Res. 2016;76(11):3265–3276. doi:10.1158/0008-5472.CAN-15-260127197151
   PubMed Web of Science ®Google Scholar
• Bian XL, Chen HZ, Yang PB, et al. Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation. Nat Commun. 2017;8:14420. doi:10.1038/ncomms1442028240261
   PubMed Web of Science ®Google Scholar
• Liao K, Deng S, Xu L, et al. A feedback circuitry between polycomb signaling and fructose-1, 6-bisphosphatase enables hepatic and renal tumorigenesis. Cancer Res. 2020;80(4):675–688. doi:10.1158/0008-5472.CAN-19-206031948940
   PubMed Web of Science ®Google Scholar
• Liu MX, Jin L, Sun SJ, et al. Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma. Oncogene. 2018;37(12):1637–1653. doi:10.1038/s41388-017-0070-629335519
   PubMed Web of Science ®Google Scholar
• Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157. doi:10.1186/s12943-019-1089-931711497
   PubMed Web of Science ®Google Scholar
• Sahu A, Kwon I, Tae G. Improving cancer therapy through the nanomaterials-assisted alleviation of hypoxia. Biomaterials. 2020;228:119578. doi:10.1016/j.biomaterials.2019.11957831678843
   PubMed Web of Science ®Google Scholar
• Briggs KJ, Koivunen P, Cao S, et al. Paracrine induction of HIF by glutamate in breast cancer: EglN1 senses cysteine. Cell. 2016;166(1):126–139. doi:10.1016/j.cell.2016.05.04227368101
   PubMed Web of Science ®Google Scholar
• Shang RZ, Qu SB, Wang DS. Reprogramming of glucose metabolism in hepatocellular carcinoma: progress and prospects. World J Gastroenterol. 2016;22(45):9933–9943. doi:10.3748/wjg.v22.i45.993328018100
   PubMed Web of Science ®Google Scholar
• Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006;3(3):187–197. doi:10.1016/j.cmet.2006.01.01216517406
   PubMed Web of Science ®Google Scholar
• Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011;14(3):191–201. doi:10.1016/j.drup.2011.03.00121466972
   PubMed Web of Science ®Google Scholar
• Qing G, Simon MC. Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev. 2009;19(1):60–66. doi:10.1016/j.gde.2008.12.00119167211
   PubMed Web of Science ®Google Scholar
• Dabral S, Muecke C, Valasarajan C, et al. A RASSF1A-HIF1alpha loop drives Warburg effect in cancer and pulmonary hypertension. Nat Commun. 2019;10(1):2130. doi:10.1038/s41467-019-10044-z31086178
   PubMedGoogle Scholar
• Zhang X, Li Y, Ma Y, et al. Yes-associated protein (YAP) binds to HIF-1alpha and sustains HIF-1alpha protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress. J Exp Clin Cancer Res. 2018;37(1):216. doi:10.1186/s13046-018-0892-230180863
   PubMedGoogle Scholar
• Shi DY, Xie FZ, Zhai C, Stern JS, Liu Y, Liu SL. The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells. Mol Cancer. 2009;8:32. doi:10.1186/1476-4598-8-3219497135
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang Y, Li X, Yang A, Li Z, Wang D. The anti-carcinogenesis properties of erianin in the modulation of oxidative stress-mediated apoptosis and immune response in liver cancer. Aging (Albany NY). 2019;11(22):10284–10300. doi:10.18632/aging.10245631754081
   PubMedGoogle Scholar
• Lee D, Xu IM, Chiu DK, et al. Induction of oxidative stress through inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma. Hepatology. 2019;69(4):1768–1786. doi:10.1002/hep.3046730561826
   PubMed Web of Science ®Google Scholar
• Huang Q, Zhan L, Cao H, et al. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways. Autophagy. 2016;12(6):999–1014. doi:10.1080/15548627.2016.116631827124102
   PubMed Web of Science ®Google Scholar
• Shen J, Chen M, Lee D, et al. Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression. Gut. 2020;69(2):329–342. doi:10.1136/gutjnl-2019-31866831439637
   PubMed Web of Science ®Google Scholar
• Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015;356(2 Pt A):156–164. doi:10.1016/j.canlet.2014.04.00124732809
   PubMed Web of Science ®Google Scholar
• Chang H, Li J, Qu K, et al. CRIF1 overexpression facilitates tumor growth and metastasis through inducing ROS/NFkappaB pathway in hepatocellular carcinoma. Cell Death Dis. 2020;11(5):332. doi:10.1038/s41419-020-2528-732382077
   PubMed Web of Science ®Google Scholar
• Geng X, Geng Z, Li H, Zhang Y, Li J, Chang H. Over-expression of TFB2M facilitates cell growth and metastasis via activating ROS-Akt-NF-kappaB signalling in hepatocellular carcinoma. Liver Int. 2020;40(7):1756–1769. doi:10.1111/liv.1444032174027
   PubMed Web of Science ®Google Scholar
• Zheng X, Li C, Yu K, et al. Aquaporin-9, mediated by IGF2, suppresses liver cancer stem cell properties via augmenting ROS/beta-catenin/FOXO3a signaling. Mol Cancer Res. 2020;18(7):992–1003. doi:10.1158/1541-7786.MCR-19-118032229502
   PubMed Web of Science ®Google Scholar
• Fuhrmann DC, Brune B. Mitochondrial composition and function under the control of hypoxia. Redox Biol. 2017;12:208–215. doi:10.1016/j.redox.2017.02.01228259101
   PubMed Web of Science ®Google Scholar
• Kung-Chun Chiu D, Pui-Wah Tse A, Law CT, et al. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. Cell Death Dis. 2019;10(12):934. doi:10.1038/s41419-019-2155-331819034
   PubMedGoogle Scholar
• Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem. 2008;283(42):28106–28114. doi:10.1074/jbc.M80350820018718909
   PubMed Web of Science ®Google Scholar
• Dang CV. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found Symp Proc. 2007;(4):35–53.18811052
   PubMedGoogle Scholar
• Brahimi-Horn MC, Giuliano S, Saland E, et al. Knockout of Vdac1 activates hypoxia-inducible factor through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation. Cancer Metab. 2015;3:8. doi:10.1186/s40170-015-0133-526322231
   PubMedGoogle Scholar
• Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell. 2007;129(1):111–122. doi:10.1016/j.cell.2007.01.04717418790
   PubMed Web of Science ®Google Scholar
• Tello D, Balsa E, Acosta-Iborra B, et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1alpha decreases oxygen consumption by inhibiting Complex I activity. Cell Metab. 2011;14(6):768–779. doi:10.1016/j.cmet.2011.10.00822100406
   PubMed Web of Science ®Google Scholar
• Zhang H, Bosch-Marce M, Shimoda LA, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem. 2008;283(16):10892–10903. doi:10.1074/jbc.M80010220018281291
   PubMed Web of Science ®Google Scholar
• Dai W, Xu L, Yu X, et al. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism. J Hepatol. 2020;72(5):909–923. doi:10.1016/j.jhep.2019.12.01531899205
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007;104(49):19345–19350. doi:10.1073/pnas.070974710418032601
   PubMed Web of Science ®Google Scholar
• Levy PL, Duponchel S, Eischeid H, et al. Hepatitis C virus infection triggers a tumor-like glutamine metabolism. Hepatology. 2017;65(3):789–803. doi:10.1002/hep.2894927863447
   PubMed Web of Science ®Google Scholar
• Shanware NP, Bray K, Eng CH, et al. Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion. Nat Commun. 2014;5:4900. doi:10.1038/ncomms590025254627
   PubMed Web of Science ®Google Scholar
• Li B, Cao Y, Meng G, et al. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine. 2019;39:239–254. doi:10.1016/j.ebiom.2018.11.06330555042
   PubMed Web of Science ®Google Scholar
• Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010;9(6):447–464. doi:10.1038/nrd313720467424
   PubMed Web of Science ®Google Scholar
• Lippmann J, Petri K, Fulda S, Liese J. Redox modulation and induction of ferroptosis as a new therapeutic strategy in hepatocellular carcinoma. Transl Oncol. 2020;13(8):100785. doi:10.1016/j.tranon.2020.10078532416440
   PubMed Web of Science ®Google Scholar
• Pibiri M, Sulas P, Camboni T, Leoni VP, Simbula G. Alpha-lipoic acid induces endoplasmic reticulum stress-mediated apoptosis in hepatoma cells. Sci Rep. 2020;10(1):7139. doi:10.1038/s41598-020-64004-532345994
   PubMed Web of Science ®Google Scholar
• Huang X, Gan G, Wang X, Xu T, Xie W. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy. 2019;15(7):1258–1279. doi:10.1080/15548627.2019.158010530786811
   PubMed Web of Science ®Google Scholar
• Long Y, Tsai WB, Wang D, et al. Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. Cancer Lett. 2017;388:54–63. doi:10.1016/j.canlet.2016.11.02827913198
   PubMed Web of Science ®Google Scholar
• Tang L, Zeng J, Geng P, et al. Global metabolic profiling identifies a pivotal role of proline and hydroxyproline metabolism in supporting hypoxic response in hepatocellular carcinoma. Clin Cancer Res. 2018;24(2):474–485. doi:10.1158/1078-0432.CCR-17-170729084919
   PubMed Web of Science ®Google Scholar
• Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011;11(9):671–677. doi:10.1038/nrc311021833026
   PubMed Web of Science ®Google Scholar
• Savic LJ, Schobert IT, Peters D, et al. Molecular imaging of extracellular tumor pH to reveal effects of locoregional therapy on liver cancer microenvironment. Clin Cancer Res. 2020;26(2):428–438. doi:10.1158/1078-0432.CCR-19-170231582517
   PubMed Web of Science ®Google Scholar
• Coman D, Peters DC, Walsh JJ, et al. Extracellular pH mapping of liver cancer on a clinical 3T MRI scanner. Magn Reson Med. 2020;83(5):1553–1564. doi:10.1002/mrm.2803531691371
   PubMed Web of Science ®Google Scholar
• Kwon SY, Kim DY, Min JJ, Bae WK. Potential visualization of sorafenib-induced acidosis using 11C-acetate PET/CT in patients with hepatocellular carcinoma. Clin Nucl Med. 2018;43(1):31–32. doi:10.1097/RLU.000000000000187929112010
   PubMed Web of Science ®Google Scholar
• Mookerjee SA, Goncalves RLS, Gerencser AA, Nicholls DG, Brand MD. The contributions of respiration and glycolysis to extracellular acid production. Biochim Biophys Acta. 2015;1847(2):171–181. doi:10.1016/j.bbabio.2014.10.00525449966
   PubMed Web of Science ®Google Scholar
• Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech. 2011;4(6):727–732. doi:10.1242/dmm.00772422065843
   PubMed Web of Science ®Google Scholar
• Shen YC, Ou DL, Hsu C, et al. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer. 2013;108(1):72–81. doi:10.1038/bjc.2012.55923257894
   PubMed Web of Science ®Google Scholar
• Guo Y, Li X, Sun X, et al. Combined aberrant expression of NDRG2 and LDHA predicts hepatocellular carcinoma prognosis and mediates the anti-tumor effect of gemcitabine. Int J Biol Sci. 2019;15(9):1771–1786. doi:10.7150/ijbs.3509431523182
   PubMed Web of Science ®Google Scholar
• Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 2011;71(7):2550–2560. doi:10.1158/0008-5472.CAN-10-282821300765
   PubMed Web of Science ®Google Scholar
• Sonveaux P, Vegran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118(12):3930–3942. doi:10.1172/JCI3684319033663
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7(2):168–181. doi:10.1038/nrd246718167490
   PubMed Web of Science ®Google Scholar
• Viklund J, Avnet S, De Milito A. Pathobiology and therapeutic implications of tumor acidosis. Curr Med Chem. 2017;24(26):2827–2845. doi:10.2174/092986732366616122814284928031009
   PubMed Web of Science ®Google Scholar
• Svastova E, Witarski W, Csaderova L, et al. Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J Biol Chem. 2012;287(5):3392–3402. doi:10.1074/jbc.M111.28606222170054
   PubMed Web of Science ®Google Scholar
• Kuchuk O, Tuccitto A, Citterio D, et al. pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. Oncoimmunology. 2018;7(7):e1445452. doi:10.1080/2162402X.2018.144545229900055
   PubMed Web of Science ®Google Scholar
• Filatova A, Seidel S, Bogurcu N, Graf S, Garvalov BK, Acker T. Acidosis acts through HSP90 in a PHD/VHL-independent manner to promote HIF function and stem cell maintenance in glioma. Cancer Res. 2016;76(19):5845–5856. doi:10.1158/0008-5472.CAN-15-263027488520
   PubMed Web of Science ®Google Scholar
• Nadtochiy SM, Schafer X, Fu D, Nehrke K, Munger J, Brookes PS. Acidic pH is a metabolic switch for 2-hydroxyglutarate generation and signaling. J Biol Chem. 2016;291(38):20188–20197. doi:10.1074/jbc.M116.73879927510037
   PubMed Web of Science ®Google Scholar
• Mossanen JC, Kohlhepp M, Wehr A, et al. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T- and CD4(+) T-cell-dependent control of senescence. Gastroenterology. 2019;156(6):1877–1889 e1874. doi:10.1053/j.gastro.2019.01.24730710528
   PubMed Web of Science ®Google Scholar
• Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol. 2005;5(11):844–852. doi:10.1038/nri171016239903
   PubMed Web of Science ®Google Scholar
• Beyoglu D, Imbeaud S, Maurhofer O, et al. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology. 2013;58(1):229–238. doi:10.1002/hep.2635023463346
   PubMed Web of Science ®Google Scholar
• Henning AN, Roychoudhuri R, Restifo NP. Epigenetic control of CD8(+) T cell differentiation. Nat Rev Immunol. 2018;18(5):340–356. doi:10.1038/nri.2017.14629379213
   PubMed Web of Science ®Google Scholar
• Pace L, Goudot C, Zueva E, et al. The epigenetic control of stemness in CD8(+) T cell fate commitment. Science. 2018;359(6372):177–186. doi:10.1126/science.aah649929326266
   PubMed Web of Science ®Google Scholar
• Sallusto F, Cassotta A, Hoces D, Foglierini M, Lanzavecchia A. Do memory CD4 T cells keep their cell-type programming: plasticity versus fate commitment? T-cell heterogeneity, plasticity, and selection in humans. Cold Spring Harb Perspect Biol. 2018;10(3):a029421. doi:10.1101/cshperspect.a02942128432133
   PubMed Web of Science ®Google Scholar
• Becattini S, Latorre D, Mele F, et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. Science. 2015;347(6220):400–406. doi:10.1126/science.126066825477212
   PubMed Web of Science ®Google Scholar
• Wang K, Yaghi OK, Spallanzani RG, et al. Neuronal, stromal, and T-regulatory cell crosstalk in murine skeletal muscle. Proc Natl Acad Sci U S A. 2020;117(10):5402–5408.32102913
   PubMed Web of Science ®Google Scholar
• Choi JY, Eskandari SK, Cai S, et al. Regulatory CD8 T cells that recognize Qa-1 expressed by CD4 T-helper cells inhibit rejection of heart allografts. Proc Natl Acad Sci U S A. 2020;117(11):6042–6046. doi:10.1073/pnas.191895011732111690
   PubMed Web of Science ®Google Scholar
• Buck MD, O’Sullivan D, Klein Geltink RI, et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell. 2016;166(1):63–76. doi:10.1016/j.cell.2016.05.03527293185
   PubMed Web of Science ®Google Scholar
• Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460(7251):103–107. doi:10.1038/nature0809719494812
   PubMed Web of Science ®Google Scholar
• Weinberg SE, Singer BD, Steinert EM, et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature. 2019;565(7740):495–499. doi:10.1038/s41586-018-0846-z30626970
   PubMed Web of Science ®Google Scholar
• Scharping NE, Menk AV, Moreci RS, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 2016;45(2):374–388. doi:10.1016/j.immuni.2016.07.00927496732
   PubMed Web of Science ®Google Scholar
• Beier UH, Angelin A, Akimova T, et al. Essential role of mitochondrial energy metabolism in Foxp3(+) T-regulatory cell function and allograft survival. FASEB J. 2015;29(6):2315–2326. doi:10.1096/fj.14-26840925681462
   PubMed Web of Science ®Google Scholar
• Poznanski SM, Barra NG, Ashkar AA, Schertzer JD. Immunometabolism of T cells and NK cells: metabolic control of effector and regulatory function. Inflamm Res. 2018;67(10):813–828. doi:10.1007/s00011-018-1174-330066126
   PubMed Web of Science ®Google Scholar
• Ogando J, Saez ME, Santos J, et al. PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8(+) T lymphocytes. J Immunother Cancer. 2019;7(1):151. doi:10.1186/s40425-019-0628-731196176
   PubMedGoogle Scholar
• Wang S, Campos J, Gallotta M, et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci U S A. 2016;113(46):E7240–E7249. doi:10.1073/pnas.160855511327799536
   PubMed Web of Science ®Google Scholar
• Chang CH, Curtis JD, Maggi LB, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153(6):1239–1251. doi:10.1016/j.cell.2013.05.01623746840
   PubMed Web of Science ®Google Scholar
• Sukumar M, Liu J, Ji Y, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest. 2013;123(10):4479–4488. doi:10.1172/JCI6958924091329
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Bardhan K, Chatterjee P, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692. doi:10.1038/ncomms769225809635
   PubMed Web of Science ®Google Scholar
• Geiger R, Rieckmann JC, Wolf T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167(3):829–842 e813. doi:10.1016/j.cell.2016.09.03127745970
   PubMed Web of Science ®Google Scholar
• Bengsch B, Johnson AL, Kurachi M, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion. Immunity. 2016;45(2):358–373. doi:10.1016/j.immuni.2016.07.00827496729
   PubMed Web of Science ®Google Scholar
• Franchina DG, He F, Brenner D. Survival of the fittest: cancer challenges T cell metabolism. Cancer Lett. 2018;412:216–223. doi:10.1016/j.canlet.2017.10.01429074426
   PubMed Web of Science ®Google Scholar
• Pacella I, Piconese S. Immunometabolic checkpoints of treg dynamics: adaptation to microenvironmental opportunities and challenges. Front Immunol. 2019;10:1889. doi:10.3389/fimmu.2019.0188931507585
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Chang CH, Qiu J, O’Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229–1241. doi:10.1016/j.cell.2015.08.01626321679
   PubMed Web of Science ®Google Scholar
• Macintyre AN, Gerriets VA, Nichols AG, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 2014;20(1):61–72. doi:10.1016/j.cmet.2014.05.00424930970
   PubMed Web of Science ®Google Scholar
• Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109(9):3812–3819. doi:10.1182/blood-2006-07-03597217255361
   PubMed Web of Science ®Google Scholar
• Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253–257. doi:10.1038/nature1696926934227
   PubMed Web of Science ®Google Scholar
• Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24(5):657–671. doi:10.1016/j.cmet.2016.08.01127641098
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.10128741618
   PubMed Web of Science ®Google Scholar
• Pacella I, Procaccini C, Focaccetti C, et al. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc Natl Acad Sci U S A. 2018;115(28):E6546–E6555. doi:10.1073/pnas.172011311529941600
   PubMed Web of Science ®Google Scholar
• Liu X, Mo W, Ye J, et al. Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition. Nat Commun. 2018;9(1):249. doi:10.1038/s41467-017-02689-529339767
   PubMedGoogle Scholar
• Renner K, Singer K, Koehl GE, et al. Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. Front Immunol. 2017;8:248. doi:10.3389/fimmu.2017.0024828337200
   PubMed Web of Science ®Google Scholar
• Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72(2):320–341. doi:10.1016/j.jhep.2019.10.02131954495
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461. doi:10.1016/j.ccell.2015.03.00125858804
   PubMed Web of Science ®Google Scholar
• Xiang J, Zhang N, Sun H, et al. Disruption of SIRT7 increases the efficacy of checkpoint inhibitor via MEF2D regulation of programmed cell death 1 ligand 1 in hepatocellular carcinoma cells. Gastroenterology. 2020;158(3):664–678 e624. doi:10.1053/j.gastro.2019.10.02531678303
   PubMed Web of Science ®Google Scholar
• Itoh S, Yoshizumi T, Yugawa K, et al. Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology. 2020. doi:10.1002/hep.31206
   PubMed Web of Science ®Google Scholar
• Pauken KE, Sammons MA, Odorizzi PM, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016;354(6316):1160–1165. doi:10.1126/science.aaf280727789795
   PubMed Web of Science ®Google Scholar
• Poggio M, Hu T, Pai CC, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414–427 e413. doi:10.1016/j.cell.2019.02.01630951669
   PubMed Web of Science ®Google Scholar
• Arce Vargas F, Furness AJS, Litchfield K, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell. 2018;33(4):649–663 e644. doi:10.1016/j.ccell.2018.02.01029576375
   PubMed Web of Science ®Google Scholar
• Walker LS, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol. 2015;36(2):63–70. doi:10.1016/j.it.2014.12.00125582039
   PubMed Web of Science ®Google Scholar
• He W, Zhang H, Han F, et al. CD155T/TIGIT signaling regulates CD8(+) T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res. 2017;77(22):6375–6388. doi:10.1158/0008-5472.CAN-17-038128883004
   PubMed Web of Science ®Google Scholar
• Keating SE, Zaiatz-Bittencourt V, Loftus RM, et al. Metabolic reprogramming supports IFN-gamma production by CD56bright NK cells. J Immunol. 2016;196(6):2552–2560. doi:10.4049/jimmunol.150178326873994
   PubMed Web of Science ®Google Scholar
• Lotze MT, Buchser WJ, Liang X. Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy. 2012;8(8):1264–1266. doi:10.4161/auto.2075222660171
   PubMed Web of Science ®Google Scholar
• Easom NJW, Stegmann KA, Swadling L, et al. IL-15 overcomes hepatocellular carcinoma-induced NK cell dysfunction. Front Immunol. 2018;9:1009. doi:10.3389/fimmu.2018.0100929867983
   PubMed Web of Science ®Google Scholar
• Zhou J, Peng H, Li K, et al. Liver-resident NK cells control antiviral activity of hepatic T cells via the PD-1-PD-L1 axis. Immunity. 2019;50(2):403–417 e404. doi:10.1016/j.immuni.2018.12.02430709740
   PubMed Web of Science ®Google Scholar
• Sun C, Xu J, Huang Q, et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology. 2017;6(1):e1264562. doi:10.1080/2162402X.2016.126456228197391
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723–732. doi:10.1038/s41590-018-0132-029915296
   PubMed Web of Science ®Google Scholar
• Sun H, Huang Q, Huang M, et al. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology. 2019;70(1):168–183. doi:10.1002/hep.3034730411378
   PubMed Web of Science ®Google Scholar
• Sun H, Liu L, Huang Q, et al. Accumulation of tumor-infiltrating CD49a(+) NK cells correlates with poor prognosis for human hepatocellular carcinoma. Cancer Immunol Res. 2019;7(9):1535–1546. doi:10.1158/2326-6066.CIR-18-075731311791
   PubMed Web of Science ®Google Scholar
• Pfeifer C, Highton AJ, Peine S, et al. Natural killer cell education is associated with a distinct glycolytic profile. Front Immunol. 2018;9:3020. doi:10.3389/fimmu.2018.0302030619362
   PubMed Web of Science ®Google Scholar
• Andre P, Denis C, Soulas C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731–1743 e1713. doi:10.1016/j.cell.2018.10.01430503213
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51. doi:10.1016/j.cell.2010.03.01420371344
   PubMed Web of Science ®Google Scholar
• Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559–563. doi:10.1038/nature1349025043024
   PubMed Web of Science ®Google Scholar
• Oh KW, Currin RT, Lemasters JJ. Kupffer cells mediate increased anoxic hepatocellular killing from hyperosmolarity by an oxygen- and prostaglandin-independent mechanism. Toxicol Lett. 2000;117(1–2):95–100. doi:10.1016/S0378-4274(00)00247-211033238
   PubMed Web of Science ®Google Scholar
• Giovannini C, Bolondi L, Gramantieri L. Targeting Notch3 in hepatocellular carcinoma: molecular mechanisms and therapeutic perspectives. Int J Mol Sci. 2016;18(1):56. doi:10.3390/ijms18010056
   PubMed Web of Science ®Google Scholar
• Xiang S, Gu H, Jin L, Thorne RF, Zhang XD, Wu M. LncRNA IDH1-AS1 links the functions of c-Myc and HIF1alpha via IDH1 to regulate the Warburg effect. Proc Natl Acad Sci U S A. 2018;115(7):E1465–E1474. doi:10.1073/pnas.171125711529378948
   PubMed Web of Science ®Google Scholar
• Yu L, Kim J, Jiang L, et al. MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing. Nat Commun. 2020;11(1):708. doi:10.1038/s41467-020-14437-332024842
   PubMed Web of Science ®Google Scholar
• Liang J, Cao R, Zhang Y, et al. PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis. Nat Commun. 2016;7:12431. doi:10.1038/ncomms1243127485204
   PubMed Web of Science ®Google Scholar
• Wong KKL, Liao JZ, Verheyen EM. A positive feedback loop between Myc and aerobic glycolysis sustains tumor growth in a Drosophila tumor model. Elife. 2019;8. doi:10.7554/eLife.46315
   Web of Science ®Google Scholar
• Weng Q, Chen M, Yang W, et al. Integrated analyses identify miR-34c-3p/MAGI3 axis for the Warburg metabolism in hepatocellular carcinoma. FASEB J. 2020;34(4):5420–5434. doi:10.1096/fj.201902895R32080912
   PubMed Web of Science ®Google Scholar
• Yin Y, Sun M, Zhan X, et al. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC. J Exp Clin Cancer Res. 2019;38(1):83. doi:10.1186/s13046-019-1082-630770740
   PubMedGoogle Scholar
• Peng M, Wei-Guo T, Jin-Wu H, et al. HSP4 triggers epithelial-mesenchymal transition and promotes motility capacities of hepatocellular carcinoma cells via activating AKT. Liver Int. 2020;40(5):1211–1223.32077551
   PubMed Web of Science ®Google Scholar
• Dou C, Zhou Z, Xu Q, et al. Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca(2+)/PI3K/AKT pathway. Oncogene. 2019;38(8):1239–1255. doi:10.1038/s41388-018-0505-830250300
   PubMed Web of Science ®Google Scholar
• Cheng SC, Quintin J, Cramer RA, et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684. doi:10.1126/science.125068425258083
   PubMed Web of Science ®Google Scholar
• Liao YJ, Lee TS, Twu YC, et al. Glycine N-methyltransferase deficiency in female mice impairs insulin signaling and promotes gluconeogenesis by modulating the PI3K/Akt pathway in the liver. J Biomed Sci. 2016;23(1):69. doi:10.1186/s12929-016-0278-827716281
   PubMedGoogle Scholar
• Liu Y, Lu LL, Wen D, et al. MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming. J Hematol Oncol. 2020;13(1):12. doi:10.1186/s13045-019-0841-332033570
   PubMed Web of Science ®Google Scholar
• Kim E, Lisby A, Ma C, et al. Promotion of growth factor signaling as a critical function of beta-catenin during HCC progression. Nat Commun. 2019;10(1):1909. doi:10.1038/s41467-019-09780-z31015417
   PubMed Web of Science ®Google Scholar
• de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A. 1998;95(15):8847–8851. doi:10.1073/pnas.95.15.88479671767
   PubMed Web of Science ®Google Scholar
• Lecarpentier Y, Schussler O, Hebert JL, Vallee A. Multiple targets of the canonical WNT/beta-catenin signaling in cancers. Front Oncol. 2019;9:1248. doi:10.3389/fonc.2019.0124831803621
   PubMed Web of Science ®Google Scholar
• Xu W, Zhou W, Cheng M, et al. Hypoxia activates Wnt/beta-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma. Sci Rep. 2017;7:40446. doi:10.1038/srep4044628074862
   PubMed Web of Science ®Google Scholar
• Zhang N, Chen X. A positive feedback loop involving the LINC00346/beta-catenin/MYC axis promotes hepatocellular carcinoma development. Cell Oncol (Dordr). 2020;43(1):137–153. doi:10.1007/s13402-019-00478-431691159
   PubMed Web of Science ®Google Scholar
• Fu X, Zhu X, Qin F, et al. Linc00210 drives Wnt/beta-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner. Mol Cancer. 2018;17(1):73. doi:10.1186/s12943-018-0783-329540185
   PubMedGoogle Scholar
• Li N, Wei L, Liu X, et al. A frizzled-like cysteine-rich domain in glypican-3 mediates wnt binding and regulates hepatocellular carcinoma tumor growth in mice. Hepatology. 2019;70(4):1231–1245. doi:10.1002/hep.3064630963603
   PubMed Web of Science ®Google Scholar
• Huang JL, Fu YP, Gan W, et al. Hepatic stellate cells promote the progression of hepatocellular carcinoma through microRNA-1246-RORalpha-Wnt/beta-Catenin axis. Cancer Lett. 2020;476:140–151. doi:10.1016/j.canlet.2020.02.01232061951
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bai X, Chen W, et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis. 2013;34(5):962–973. doi:10.1093/carcin/bgt02723358852
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye X, Zhang JB, et al. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing beta-catenin expression and nuclear translocation. Oncogene. 2015;34(44):5524–5535. doi:10.1038/onc.2015.725684142
   PubMed Web of Science ®Google Scholar
• Guo Y, Wu Z, Shen S, et al. Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy. Nat Commun. 2018;9(1):3430. doi:10.1038/s41467-018-05764-730143633
   PubMedGoogle Scholar
• Batlle E, Massague J. Transforming growth factor-beta signaling in immunity and cancer. Immunity. 2019;50(4):924–940. doi:10.1016/j.immuni.2019.03.02430995507
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang Y, Dou C, et al. Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma. Theranostics. 2018;8(17):4649–4663. doi:10.7150/thno.2678930279729
   PubMed Web of Science ®Google Scholar
• Soukupova J, Malfettone A, Hyroššová P, et al. Role of the transforming growth factor-β in regulating hepatocellular carcinoma oxidative metabolism. Sci Rep. 2017;7(1). doi:10.1038/s41598-017-12837-y.
   PubMed Web of Science ®Google Scholar
• Chae KS, Kang MJ, Lee JH, et al. Opposite functions of HIF-alpha isoforms in VEGF induction by TGF-beta1 under non-hypoxic conditions. Oncogene. 2011;30(10):1213–1228. doi:10.1038/onc.2010.49821057546
   PubMed Web of Science ®Google Scholar
• Lin J, Cao S, Wang Y, et al. Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1alpha/VEGFA signalling in hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):113. doi:10.1186/s13046-018-0727-129866133
   PubMedGoogle Scholar
• Xuan Z, Zhao L, Li Z, et al. EPS8L3 promotes hepatocellular carcinoma proliferation and metastasis by modulating EGFR dimerization and internalization. Am J Cancer Res. 2020;10(1):60–77.32064153
   PubMed Web of Science ®Google Scholar
• Zhou HJ, Xu Z, Wang Z, et al. SUMOylation of VEGFR2 regulates its intracellular trafficking and pathological angiogenesis. Nat Commun. 2018;9(1):3303. doi:10.1038/s41467-018-05812-230120232
   PubMedGoogle Scholar
• Krzywinska E, Kantari-Mimoun C, Kerdiles Y, et al. Loss of HIF-1alpha in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis. Nat Commun. 2017;8(1):1597. doi:10.1038/s41467-017-01599-w29150606
   PubMedGoogle Scholar
• Zhang L, Chen J, Yong J, Qiao L, Xu L, Liu C. An essential role of RNF187 in Notch1 mediated metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):384. doi:10.1186/s13046-019-1382-x31477177
   PubMed Web of Science ®Google Scholar
• Moriyama H, Moriyama M, Ozawa T, et al. Notch signaling enhances stemness by regulating metabolic pathways through modifying p53, NF-kappaB, and HIF-1alpha. Stem Cells Dev. 2018;27(13):935–947. doi:10.1089/scd.2017.026029717634
   PubMed Web of Science ®Google Scholar
• Landor SK, Lendahl U. The interplay between the cellular hypoxic response and Notch signaling. Exp Cell Res. 2017;356(2):146–151. doi:10.1016/j.yexcr.2017.04.03028456549
   PubMed Web of Science ®Google Scholar
• Yang SL, Ren QG, Zhang T, et al. Hepatitis B virus X protein and hypoxia-inducible factor-1alpha stimulate Notch gene expression in liver cancer cells. Oncol Rep. 2017;37(1):348–356. doi:10.3892/or.2016.521127840976
   PubMed Web of Science ®Google Scholar
• Jin M, Wang J, Ji X, et al. MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):136. doi:10.1186/s13046-019-1135-x30909929
   PubMedGoogle Scholar
• Chen Z, Zuo X, Pu L, et al. Hypomethylation-mediated activation of cancer/testis antigen KK-LC-1 facilitates hepatocellular carcinoma progression through activating the Notch1/Hes1 signalling. Cell Prolif. 2019;52(3):e12581. doi:10.1111/cpr.1258130895661
   PubMed Web of Science ®Google Scholar
• Zhou J, Zheng X, Feng M, et al. Upregulated MMP28 in hepatocellular carcinoma promotes metastasis via Notch3 signaling and predicts unfavorable prognosis. Int J Biol Sci. 2019;15(4):812–825. doi:10.7150/ijbs.3133530906212
   PubMed Web of Science ®Google Scholar
• Ye YC, Zhao JL, Lu YT, et al. NOTCH signaling via WNT regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma. Cancer Res. 2019;79(16):4160–4172. doi:10.1158/0008-5472.CAN-18-169131266773
   PubMed Web of Science ®Google Scholar
• Chen H, Wu D, Bao L, et al. 6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming. Biomed Pharmacother. 2019;111:1353–1358. doi:10.1016/j.biopha.2019.01.02830841449
   PubMed Web of Science ®Google Scholar
• Jin X, Moskophidis D, Mivechi NF. Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. Cell Metab. 2011;14(1):91–103. doi:10.1016/j.cmet.2011.03.02521723507
   PubMed Web of Science ®Google Scholar
• Ma X, Qiu Y, Sun Y, et al. NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway. Cell Death Dis. 2020;11(3):174. doi:10.1038/s41419-020-2368-532144252
   PubMed Web of Science ®Google Scholar
• Gao L, Lv G, Li R, et al. Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK/mTOR dependent autophagy activation. Cancer Lett. 2019;454:215–223. doi:10.1016/j.canlet.2019.04.00930980867
   PubMed Web of Science ®Google Scholar
• Bort A, Sanchez BG, Mateos-Gomez PA, Vara-Ciruelos D, Rodriguez-Henche N, Diaz-Laviada I. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib. Mol Oncol. 2019;13(5):1311–1331. doi:10.1002/1878-0261.1248830959553
   PubMed Web of Science ®Google Scholar
• Li C, Huang Z, Zhu L, et al. The contrary intracellular and extracellular functions of PEDF in HCC development. Cell Death Dis. 2019;10(10):742. doi:10.1038/s41419-019-1976-431582735
   PubMedGoogle Scholar
• Fang G, Zhang P, Liu J, et al. Inhibition of GSK-3beta activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling. Cancer Lett. 2019;463:11–26. doi:10.1016/j.canlet.2019.08.00331404613
   PubMed Web of Science ®Google Scholar
• Qiao A, Jin X, Pang J, Moskophidis D, Mivechi NF. The transcriptional regulator of the chaperone response HSF1 controls hepatic bioenergetics and protein homeostasis. J Cell Biol. 2017;216(3):723–741. doi:10.1083/jcb.20160709128183717
   PubMed Web of Science ®Google Scholar
• Garten A, Grohmann T, Kluckova K, Lavery GG, Kiess W, Penke M. Sorafenib-induced apoptosis in hepatocellular carcinoma is reversed by SIRT1. Int J Mol Sci. 2019;20(16):4048. doi:10.3390/ijms20164048
   PubMed Web of Science ®Google Scholar
• Singh L, Aldosary S, Saeedan AS, Ansari MN, Kaithwas G. Prolyl hydroxylase 2: a promising target to inhibit hypoxia-induced cellular metabolism in cancer cells. Drug Discov Today. 2018;23(11):1873–1882. doi:10.1016/j.drudis.2018.05.01629772209
   PubMed Web of Science ®Google Scholar
• Liu Y, Jiang Y, Zhang M, Tang Z, He M, Bu W. Modulating hypoxia via nanomaterials chemistry for efficient treatment of solid tumors. Acc Chem Res. 2018;51(10):2502–2511. doi:10.1021/acs.accounts.8b0021430234960
   PubMed Web of Science ®Google Scholar
• Luo W, Zhong J, Chang R, Hu H, Pandey A, Semenza GL. Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but not HIF-2alpha. J Biol Chem. 2010;285(6):3651–3663. doi:10.1074/jbc.M109.06857719940151
   PubMed Web of Science ®Google Scholar
• Albadari N, Deng S, Li W. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov. 2019;14(7):667–682. doi:10.1080/17460441.2019.161337031070059
   PubMed Web of Science ®Google Scholar
• Oh SY, Seok JY, Choi YS, Lee SH, Bae JS, Lee YM. The histone methyltransferase inhibitor BIX01294 inhibits HIF-1alpha stability and angiogenesis. Mol Cells. 2015;38(6):528–534. doi:10.14348/molcells.2015.002626013382
   PubMed Web of Science ®Google Scholar
• Sapra P, Kraft P, Pastorino F, et al. Potent and sustained inhibition of HIF-1alpha and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis. 2011;14(3):245–253. doi:10.1007/s10456-011-9209-121452059
   PubMed Web of Science ®Google Scholar
• Lee SH, Jee JG, Bae JS, Liu KH, Lee YM. A group of novel HIF-1alpha inhibitors, glyceollins, blocks HIF-1alpha synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding. J Cell Physiol. 2015;230(4):853–862. doi:10.1002/jcp.2481325204544
   PubMed Web of Science ®Google Scholar
• Fang J, Xia C, Cao Z, Zheng JZ, Reed E, Jiang BH. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 2005;19(3):342–353. doi:10.1096/fj.04-2175com15746177
   PubMed Web of Science ®Google Scholar
• Tang W, Zhao G. Small molecules targeting HIF-1alpha pathway for cancer therapy in recent years. Bioorg Med Chem. 2020;28(2):115235. doi:10.1016/j.bmc.2019.11523531843464
   PubMed Web of Science ®Google Scholar
• Feng J, Dai W, Mao Y, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1alpha/PPAR-gamma/PKM2-mediated glycolysis. J Exp Clin Cancer Res. 2020;39(1):24. doi:10.1186/s13046-020-1528-x32000827
   PubMed Web of Science ®Google Scholar
• Deng F, Chen D, Wei X, et al. Development and validation of a prognostic classifier based on HIF-1 signaling for hepatocellular carcinoma. Aging (Albany NY). 2020;12:3431.32084009
   PubMedGoogle Scholar
• Yang J, Jin X, Yan Y, et al. Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression. Sci Rep. 2017;7:43864. doi:10.1038/srep4386428262837
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhang Y, Wang C, et al. Overexpression of PCK1 gene antagonizes hepatocellular carcinoma through the activation of gluconeogenesis and suppression of glycolysis pathways. Cell Physiol Biochem. 2018;47(1):344–355. doi:10.1159/00048981129768256
   PubMedGoogle Scholar
• Taylor S, Spugnini EP, Assaraf YG, Azzarito T, Rauch C, Fais S. Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat. 2015;23:69–78. doi:10.1016/j.drup.2015.08.00426341193
   PubMed Web of Science ®Google Scholar
• Estrella V, Chen T, Lloyd M, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73(5):1524–1535. doi:10.1158/0008-5472.CAN-12-279623288510
   PubMed Web of Science ®Google Scholar
• Silva AS, Yunes JA, Gillies RJ, Gatenby RA. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res. 2009;69(6):2677–2684. doi:10.1158/0008-5472.CAN-08-239419276380
   PubMed Web of Science ®Google Scholar
• Chao M, Wu H, Jin K, et al. A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis. Elife. 2016;5. doi:10.7554/eLife.15691
   Web of Science ®Google Scholar
• Lu ZN, Tian B, Guo XL. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol. 2017;80(5):925–937. doi:10.1007/s00280-017-3426-228861639
   PubMed Web of Science ®Google Scholar
• Li D, Li N, Zhang YF, et al. Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. Gastroenterology. 2020.
   Web of Science ®Google Scholar
• Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: primed to make a difference? Cancer. 2016;122(3):367–377. doi:10.1002/cncr.2976926540029
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88. doi:10.1016/j.jhep.2013.02.02223466307
   PubMed Web of Science ®Google Scholar
• Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730. doi:10.3389/fphar.2017.0073029093678
   PubMed Web of Science ®Google Scholar
• Xu H, Tan P, Zheng X, et al. Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis. Drug Des Devel Ther. 2019;13:2215–2234. doi:10.2147/DDDT.S196316
   PubMed Web of Science ®Google Scholar
• Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ. Combined locoregional-immunotherapy for liver cancer. J Hepatol. 2019;70(5):999–1007. doi:10.1016/j.jhep.2019.01.02730738077
   PubMed Web of Science ®Google Scholar
• Jansen CS, Prokhnevska N, Master VA, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576(7787):465–470. doi:10.1038/s41586-019-1836-531827286
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(1):11–31. doi:10.1038/nrclinonc.2016.6027141887
   PubMed Web of Science ®Google Scholar
• Fortunato S, Bononi G, Granchi C, Minutolo F. An update on patents covering agents that interfere with the cancer glycolytic cascade. ChemMedChem. 2018;13(21):2251–2265. doi:10.1002/cmdc.20180044730226288
   PubMed Web of Science ®Google Scholar
• Guo Z, Cheng Z, Wang J, et al. Discovery of a potent GLUT inhibitor from a library of rapafucins by using 3D microarrays. Angew Chem Int Ed Engl. 2019;58(48):17158–17162. doi:10.1002/anie.20190557831591797
   PubMed Web of Science ®Google Scholar
• Shi T, Ma Y, Cao L, et al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 2019;10(4):308. doi:10.1038/s41419-019-1549-630952834
   PubMed Web of Science ®Google Scholar
• DeWaal D, Nogueira V, Terry AR, et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun. 2018;9(1):446. doi:10.1038/s41467-017-02733-429386513
   PubMedGoogle Scholar
• Zhang Z, Li TE, Chen M, et al. MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming. Br J Cancer. 2020;122(2):209–220. doi:10.1038/s41416-019-0658-431819189
   PubMed Web of Science ®Google Scholar
• Terranova T, Feo F, Gravela E, Gabriel L. [the effect of 2-desoxyglucose on energy metabolism and protein synthesis of tumor cells and normal cells]. Z Krebsforsch. 1964;66:41–45. doi:10.1007/BF0052555914154135
   PubMedGoogle Scholar
• Yin X, Choudhury M, Kang JH, et al. Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-beta. Sci Signal. 2019;12(612):eaax4067. doi:10.1126/scisignal.aax406731848318
   PubMed Web of Science ®Google Scholar
• Agnihotri S, Mansouri S, Burrell K, et al. Ketoconazole and posaconazole selectively target HK2-expressing glioblastoma cells. Clin Cancer Res. 2019;25(2):844–855. doi:10.1158/1078-0432.CCR-18-185430322879
   PubMed Web of Science ®Google Scholar
• Kunjithapatham R, Geschwind JF, Rao PP, Boronina TN, Cole RN, Ganapathy-Kanniappan S. Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model. BMC Res Notes. 2013;6:277. doi:10.1186/1756-0500-6-27723866825
   PubMedGoogle Scholar
• Yi W, Clark PM, Mason DE, et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science. 2012;337(6097):975–980. doi:10.1126/science.122227822923583
   PubMed Web of Science ®Google Scholar
• Hu J, Zeng Z, Xia Q, et al. Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1alpha/PFKFB3/PFK1 pathway. Life Sci. 2019;239:116966. doi:10.1016/j.lfs.2019.11696631626790
   PubMed Web of Science ®Google Scholar
• Su Q, Luo S, Tan Q, et al. The role of pyruvate kinase M2 in anticancer therapeutic treatments. Oncol Lett. 2019;18(6):5663–5672. doi:10.3892/ol.2019.1094831788038
   PubMed Web of Science ®Google Scholar
• Shang D, Wu J, Guo L, Xu Y, Liu L, Lu J. Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2. Int J Oncol. 2017;50(5):1848–1856. doi:10.3892/ijo.2017.395028393220
   PubMed Web of Science ®Google Scholar
• Li L, Kang L, Zhao W, et al. miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect. Cancer Lett. 2017;400:89–98. doi:10.1016/j.canlet.2017.04.03428461244
   PubMed Web of Science ®Google Scholar
• Boudreau A, Purkey HE, Hitz A, et al. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nat Chem Biol. 2016;12(10):779–786. doi:10.1038/nchembio.214327479743
   PubMed Web of Science ®Google Scholar
• Grasmann G, Smolle E, Olschewski H, Leithner K. Gluconeogenesis in cancer cells - Repurposing of a starvation-induced metabolic pathway? Biochim Biophys Acta Rev Cancer. 2019;1872(1):24–36. doi:10.1016/j.bbcan.2019.05.00631152822
   PubMed Web of Science ®Google Scholar
• Duda P, Janczara J, McCubrey JA, Gizak A, Rakus D. The reverse Warburg effect is associated with Fbp2-dependent Hif1alpha regulation in cancer cells stimulated by fibroblasts. Cells. 2020;9(1):205. doi:10.3390/cells9010205
   PubMed Web of Science ®Google Scholar
• Tuo L, Xiang J, Pan X, et al. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27(Kip1) axis. J Exp Clin Cancer Res. 2019;38(1):50. doi:10.1186/s13046-019-1029-y30717766
   PubMedGoogle Scholar
• Leithner K. Epigenetic marks repressing gluconeogenesis in liver and kidney cancer. Cancer Res. 2020;80(4):657–658. doi:10.1158/0008-5472.CAN-19-395332060227
   PubMed Web of Science ®Google Scholar
• Shang F, Liu M, Li B, et al. The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells. Cancer Chemother Pharmacol. 2016;77(5):1087–1096. doi:10.1007/s00280-016-3030-x27071921
   PubMed Web of Science ®Google Scholar
• Srikantan S, Deng Y, Cheng ZM, et al. The tumor suppressor TMEM127 regulates insulin sensitivity in a tissue-specific manner. Nat Commun. 2019;10(1):4720. doi:10.1038/s41467-019-12661-031624249
   PubMedGoogle Scholar